The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins

Author： Biswas Swethajit   Killick Emma   Jochemsen Aart G   Lunec John  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.23, Iss.5, 2014-05, pp. : 629-645

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches

By  

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 2, 2005-04 ,pp. : 141-149

Bentham Science Publishers

Access to resources Recommend Favorite

STATUS AND FUTURE CONCERNS OF CLINICAL AND ENVIRONMENTAL ALUMINUM TOXICOLOGY

By Flaten Trond Peder   Alfrey Allen C.   Birchall J. Derek   Savory John   Yokel Robert A.  

Journal of Toxicology and Environmental Health, Vol. 48, Iss. 6, 1996-08 ,pp. : 527-542

Taylor & Francis Ltd

Access to resources Recommend Favorite

Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules

By  

Current Medicinal Chemistry, Vol. 17, Iss. 28, 2010-09 ,pp. : 3142-3154

Bentham Science Publishers

Access to resources Recommend Favorite

Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches

By  

Current Medicinal Chemistry, Vol. 22, Iss. 24, 2015-01 ,pp. : 2871-2901

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical developments and future of the COX-2 inhibitor drugs

By Goldstein Jerome  

Inflammopharmacology, Vol. 9, Iss. 1-2, 2001-05 ,pp. : 91-99

VSP

Access to resources Recommend Favorite